Cimetidine injection

This product is a representative of a new class of drugs, namely histamine H2-receptor antagonists, which were first used to block the effect of histamine on parietal cell H2-receptors through a competitive inhibition mechanism. This product does not have typical anticholinergic pharmacological effects.

The main ingredient of this product is cimetidine, and its chemical name is: N-methyl-N-[2[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]-N-cyanoguanidine.

This product is a colorless to light yellow clear liquid.

This product is suitable for the treatment of clearly diagnosed duodenal ulcer and gastric ulcer; patients with recurrence of duodenal ulcer after short-term treatment; patients with persistent gastroesophageal reflux disease who are ineffective in anti-reflux measures and single drug treatment such as antacids; prevention of stress ulcers and bleeding in critically ill patients; gastrinoma (Zollinger-Ellison syndrome).

Intravenous drip. 0.2g of this product is diluted with 5% glucose injection or 0.9% sodium chloride injection or glucose sodium chloride injection 250~500ml and then intravenously dripped, the drip rate is 14mg/kg per hour, 0.2~0.6g each time. Intravenous injection. Dilute with 20ml of the above solution and slowly inject intravenously (23 minutes), once every 6 hours, 0.2g each time. Intramuscular injection. 0.2g once, once every 6 hours.

The more common adverse reactions include diarrhea, dizziness, fatigue, headache and rash.

It is contraindicated for those who are allergic to cimetidine.

Precautions for children: Use with caution in children. Precautions for pregnancy and lactation: This product can pass through the placental barrier and enter breast milk, causing liver dysfunction in the fetus and infant, so it is contraindicated. Precautions for the elderly: Use with caution in elderly patients. The interval between medications can be extended and the dosage can be reduced as appropriate.

Cimetidine can change the pharmacokinetic and pharmacodynamic responses of some drugs by changing their absorption, hepatic metabolism, and renal tubular secretion. Cimetidine can affect the hepatic cytochrome P-450 oxidase system and affect renal tubular secretion. It can delay the excretion of drugs, thereby increasing the plasma concentrations of some co-administered drugs. For drugs with a small therapeutic dose range, such as warfarin anticoagulants, phenytoin, theophylline, lidocaine, quinidine, procainamide, flecainide, and nifedipine, toxic reactions are occasionally seen. When warfarin anticoagulants are used, the prothrombin time should be closely checked. When used with cimetidine, the dose of the anticoagulant should be appropriately adjusted. For the following other drugs, when starting or stopping co-administration with cimetidine, the plasma levels of the drug should be closely monitored and the dose adjusted if necessary. These drugs affected by cimetidine include beta blockers, calcium channel blockers, tricyclic antidepressants, benzodiazepines, chloramphenicol, and metformin. Although these drugs increase their plasma levels when used in combination with cimetidine, clinically significant effects are rarely seen. Particular caution should be exercised in elderly patients with liver or kidney disease.

seal

2ml:0.2g

24 months

Shandong FANGMING Pharmaceutical Group Co., Ltd.

• Founded in:

  2000-07-07

• Address:

  Fangming Section, Huanghe Road, Dongming County, Shandong Province

• Tax NO.:

  91371700724268643E

• Registered Funds:

  216.829902 yuan

• Website:

  Log in to view

• Email:

  Log in to view